LUCENCE HEALTH INC.

Company Overview

Lucence Health Inc., founded in 2016, is developing liquid biopsy-based cancer diagnostics.

Tests offered include somatic cancer tests (LiquidHallmark, LiquidMark, Liquid Screen & Track, NPC Gold), inherited cancer tests (LumiRisk, LumiFocus) and companion diagnostics tests (LumiBRCA and THERA).

Lucence has been very active in forming strategic partnerships including the following: Quest Laboratories (June 2018, Quest to offer liquid biopsy tests for cancer detection and treatment in the Asia region), National Cancer Center Singapore (July 2018, working together to improve liquid biopsy genetic testing for breast and gynecological cancers in Asian women), Bangkok Molecular Genetics (July 2018, distribution agreement for liquid biopsy diagnostics in Thailand), AstraZeneca Singapore (December 2017, collaborating on offering liquid biopsy BRCA testing to women in Singapore who have ovarian cancer), NovogeneAIR (June 2018, developing NGS-based tests for precision medicine treatment for Asia market), Singapore Diagnostics (August 2018, distributing Lucence’s liquid biopsy tests in the Philippines), and Mascots Medical and Laboratory Centre (September 2018, distributing Lucence’s liquid biopsy tests in Myanmar).

Lucence’s proprietary technology platform identifies PD-L1 rearrangement; its multiplex immunofluorescence technology enables prediction of anti-PD1/PD-L1 treatment outcomes.

In June 2018, Lucence formed an alliance with NovogeneAIR Genomics Singapore to develop NGS-based assays for precision cancer treatment for the Asian market. The tests developed will analyze the genetics of cancer tissue and focus on cancers prevalent in Asia. NovogeneAIT Genomics Singapore is a joint venture between Novogene and AITbiotech that operates a high-throughput NGS center in Singapore.

In November 2019, Lucence formed a partnership with MEDx Translational Medicine covering the development of companion diagnostic cancer tests in China. The companies agreed to co-develop companion diagnostic tests for PD-L1 rearrangement to be used with anti-PD1/PD-L1 cancer immune-therapeutics.

Company's Business Segments

• Multi-Cancer Screening : This segment includes Next-generation sequencing, PCR technology to cure different cancer types called Nasopharyngeal Cancer, Inherited Cancers, Hematological Malignancies and others.